In a move that may have significant implications for health care costs, Sandoz has asked the US Supreme Court to resolve a contentious dispute over a rule for launching biosimilars. Specifically, Sandoz wants the court to decide when a drug maker that wants to sell a biosimilar medicine must give notice to the manufacturer of the brand-name version about its product launch.
Read Full Article »
